Latest news

• FDA opens door to COVID-19 booster jabs

  With the Delta variant of SARS-CoV-2 (B.1.617.2) gaining the upper hand across both the US and Europe, drug regulators have been looking at the data around ... The Centers for Disease Control recently announced that the Delta variant was the predominant

• One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

  Meanwhile, two doses of the AZ vaccine were found to be 74.5% effective against symptomatic disease from the Alpha variant and 67% against the Delta variant. ... around 48% effective against symptomatic disease caused by the Alpha variant and 30% against

• Pfizer, BioNTech eye US approval for COVID-19 booster dose

  Recently published findings from Israel’s Health Ministry suggests that Pfizer/BioNTech’s COVID-19 vaccine is less effective against the Delta variant. ... doses. In addition, lab studies published last month found the antibodies produced by

• Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant

  Data suggests vaccine is 64% effective at preventing infection caused by Delta variant after two doses. ... The AZ vaccine was 92% effective against hospitalisation or death from the Delta variant after two doses.

• Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall

  The phase 3 results showed that COVAXIN-vaccinated individuals achieved greater protection against the Delta (B.1.617.2) and Beta (B.1.351) variants compared to those with previous natural ... infections. Overall, the vaccine demonstrated 65.2% efficacy